» Articles » PMID: 31084977

Risk Factors for Recurrence of Ameloblastoma: a Long-term Follow-up Retrospective Study

Overview
Date 2019 May 16
PMID 31084977
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Ameloblastoma is a benign odontogenic tumour showing locally aggressive characteristics. This retrospective study was performed to investigate the long-term treatment outcomes of ameloblastoma and to evaluate the risk factors for recurrence. The study was conducted in the Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, the University of Hong Kong and covered the years 1990-2017. Patient demographic data, radiographic pattern and findings, clinical findings, tumour site and size, World Health Organization classification, treatment modality, histological pattern, duration of follow-up, and timing of recurrence were recorded and analyzed. The potential risk factors were analyzed by Kaplan-Meier and Cox regression tests. The cases of a total of 128 patients were reviewed; 65 were male and 63 were female. The mean follow-up period was 117 months. The 5-, 10-, and 15-year recurrence rates were 9.3%, 17.6%, and 24.4%, respectively. Kaplan-Meier and Cox regression tests showed that recurrence was significantly associated with radiographic pattern, tumour size, and treatment modality. Multiple regression analysis for these three variables demonstrated that treatment modality was the only independent prognostic factor for recurrence. This study showed that radical resection is the only significant factor for a low recurrence rate of ameloblastoma and patients require long-term follow-up for late-onset recurrence.

Citing Articles

Clinicopathological and Immunohistochemical Risk Predictors for Ameloblastoma Recurrence.

Pires H, Franca G, Morais H, Silva W, Freitas R, Galvao H Head Neck Pathol. 2025; 19(1):22.

PMID: 39960551 PMC: 11832845. DOI: 10.1007/s12105-024-01743-1.


Bcl-2 and galectin-3 expression is associated with recurrence of ameloblastoma.

Mahdavi N, Saffar H, Derakhshan S, Saffar H, Heidari N Dent Res J (Isfahan). 2025; 21():69.

PMID: 39802810 PMC: 11722749. DOI: 10.4103/drj.drj_706_23.


Factors related to risk of recurrence and recurrence free survival in ameloblastoma of the Jaws: A single centre retrospective analysis.

Bera R, Tiwari P Oral Maxillofac Surg. 2024; 29(1):22.

PMID: 39739058 DOI: 10.1007/s10006-024-01321-3.


Surgical management of conventional ameloblastoma: a retrospective cohort study over the past 21 years.

Leite-Lima F, Martins-Chaves R, Castro W, Gomez R Oral Maxillofac Surg. 2024; 29(1):4.

PMID: 39495234 DOI: 10.1007/s10006-024-01296-1.


NKG2D (Natural Killer Group 2, Member D) ligand expression and ameloblastoma recurrence: a retrospective immunohistological pilot study.

Kim M, Jeon S, Lee H, Ri H, Cho A, Park E BMC Oral Health. 2024; 24(1):1102.

PMID: 39289711 PMC: 11409757. DOI: 10.1186/s12903-024-04873-8.